Current Issue : July-September Volume : 2026 Issue Number : 3 Articles : 5 Articles
Background/Objectives: Nutraceuticals, consisting of bioactive compounds or materials, are increasingly regarded as promising strategies for the prevention and management of diabetes. This study aimed to evaluate the antidiabetic potential of a nutraceutical formulation (Sugar Care, SC) composed of indigestible maltodextrin, pumpkin extract, and bitter melon extract, using a type 2 diabetic mouse model. Methods: A starch postprandial model in fasted normal mice was first used to assess postprandial glycemic response. Oral administration of SC at 820 and 1230 mg/kg was applied for two weeks prior to starch challenge. Subsequently, male db/db mice were randomly assigned to a diabetic control group or an SC-treated group (820 mg/kg; n = 8 per group) for four weeks. Glucose tolerance, fasting glucose and insulin levels, homeostasis model assessment of insulin resistance (HOMA-IR), lipid profile, fructosamine, and thiobarbituric acid reactive substances (TBARSs) were evaluated. Results: SC at 820 and 1230 mg/kg significantly ameliorated starch-induced postprandial hyperglycemia in normal mice (p < 0.05). In db/db mice, fourweek administration of SC significantly improved glucose tolerance and reduced fasting hyperinsulinemia and HOMA-IR values (p < 0.05). SC treatment also significantly decreased plasma fructosamine and TBARS levels, as well as total cholesterol and low-density lipoprotein cholesterol concentrations (p < 0.05). Conclusions: These findings provide preclinical evidence that this multi-component nutraceutical formulation improves glucose intolerance, insulin resistance, and dyslipidemia in a genetic model of type 2 diabetes. Further mechanistic and translational studies are warranted....
Background/Objectives: Advanced glycation end products (AGEs) and oxidative stress increase with aging and are implicated in Alzheimer’s disease (AD). We developed an anti-glycation blend using LC-MS-based screening and assessed its effects on oxidative and glycation-related biomarkers in humans. Methods: Twelve candidate compounds were screened in a BSA–glucose model using LC-MS peptide mapping to quantify lysine glycation and rank inhibitory activity. The top candidates were combined into a three-compound blend (quercetin, rutin, genistein). In a randomized, double-blind, placebo-controlled 3-month trial, older healthy adults (n = 30) and individuals with AD (n = 30) received anti-AGE blend (n = 15 in older group and n = 15 in AD group) or placebo (n = 15 in older group and n = 15 in AD group). Serum malondialdehyde and urinary Nε-(carboxymethyl)lysine were measured pre–post intervention. Pre/post and between-arm comparisons within each population were performed using REML ANOVA with Tukey post hoc tests. Serum MDA (malondialdehyde) and urinary CML (Nε-(carboxymethyl)lysine) were prespecified biomarker outcomes and are reported here as co-primary biomarker endpoints. No formal a priori sample size calculation was performed; the study size was feasibility-based. Results: LC-MS screening identified genistein, quercetin, and rutin as the most consistent inhibitors of glucose-driven BSA glycation. In older healthy adults, serum MDA decreased after anti-AGE supplementation (p < 0.001) and differed from the placebo (p < 0.01), while no change was observed within the placebo group (ns). In the AD cohort, MDA did not change significantly from baseline within either arm (ns), but postintervention MDA was lower in anti-AGE than in the placebo (p < 0.05). Urinary CML was unchanged in older healthy adults (ns in both arms), whereas in AD, it decreased after anti-AGE supplementation (p < 0.01) and differed from the placebo (p < 0.05). Conclusions: A screening-guided anti-glycation blend supplementation was associated with changes in selected biomarkers in humans: MDA decreased across cohorts, while CML decreased selectively in AD. Larger trials with extended biomarker panels and LC–MS/MS confirmation are warranted....
Morus alba L., a member of the Moraceae family, is known for its positive effects on human health, linked to the presence of different classes of secondary metabolites, including flavonoids, stilbenoids, and alkaloids, found in different parts of the plant. Stilbenoids, in particular, are mainly present at the root cortex level and, owing to their valuable activities, have attracted scientific interest in recent years. Since roots are a non-renewable source, in this study, M. alba in vitro callus cultures were established. The biomass with the appropriate growth and texture was selected for juice extraction, and the total phenol, flavonoid, and proanthocyanidin contents, along with the antioxidant activity, were estimated in the juices. The analyses throughout the callus growth cycle revealed the juice of 14-day-old calli to be the richest, resulting in the most active. In this juice, the LC-MS/MS-DAD analysis unveiled the presence of seventeen stilbenoids. Together with the data obtained by the nutritional analysis, the results showed that M. alba cell cultures have the potential to be utilised for producing innovative healthy food materials, bridging the gap between the ever-increasing natural-based-product demand and the need for more environmental, social, and economic development....
Introduction: Candida albicans commonly colonizes the female reproductive tract and may lead to systemic complications, particularly under immunocompromised conditions such as diabetes mellitus. Natural bioactive compounds with antifungal and protective properties are increasingly investigated as adjunct therapies. This study evaluated the protective potential of Spirulina platensis (SP) against C. albicans– induced renal and reproductive damage in diabetic female rats. Methods: High-performance liquid chromatography (HPLC) was used to characterize the phenolic and flavonoid profile of SP. The antifungal activity of SP was assessed in vitro against clinical C. albicans isolates. For the in vivo study, diabetes was induced in female rats, followed by C. albicans infection. Animals were orally treated with SP (75 or 150 mg/kg) for 28 days. Kidney function markers (urea, uric acid, creatinine), serum electrolytes (Na, K, Ca²), oxidative stress and antioxidant parameters (MDA, NO, protein carbonyls, total antioxidant capacity), inflammatory cytokines (TNF-α, IL-6, IFN-γ), and histopathological changes in kidney, uterus, and ovary tissues (including ovarian NF-κB immunohistochemical expression) were evaluated. Results: HPLC analysis confirmed that SP is rich in phenolic acids (chlorogenic, caffeic, protocatechuic acids) and flavonoids (rutin, quercetin, kaempferol). SP demonstrated significant in vitro antifungal activity against C. albicans. In diabetic infected rats, SP treatment significantly improved renal function and electrolyte balance, reduced oxidative stress and inflammatory markers, and ameliorated histopathological alterations in renal and reproductive tissues. Additionally, SP markedly suppressed ovarian NF-κB expression compared with infected untreated controls. Discussion: The findings indicate that Spirulina platensis exerts potent antioxidant, anti-inflammatory, and antifungal effects, contributing to protection against C. albicans–induced renal and reproductive injury in diabetic female rats. SP may represent a promising nutraceutical adjunct to conventional antifungal therapy for managing Candida-associated complications....
Background: Nutraceuticals are increasingly used in clinical practice for their antiinflammatory, antiproliferative, and antioxidant properties. This study aimed to evaluate the safety and efficacy of a fixed nutraceutical combination containing chondroitin sulfate, α-lipoic acid, astaxanthin, lycopene, escin, and omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in improving pain and quality of life in patients with chronic knee osteoarthritis (OA). Methods: This observational study included patients with chronic knee OA who were referred to the ambulatory pain clinic at Dulbecco University Hospital, Catanzaro, Italy. Participants received one tablet daily for three months. Quality of life was assessed using the 36-Item Short Form Health Survey (SF-36), and adverse drug reactions (ADRs) were evaluated using the Naranjo scale. Results: Fifty patients (20 men and 30 women; mean age, 63.6 ± 11.4 years; range, 26–88 years; mean body mass index, 26.9 ± 3.7 kg/m2) were enrolled. Pain symptoms demonstrated a statistically significant improvement over time (p < 0.01). No ADRs were reported during the study period. Conclusions: The fixed nutraceutical combination improved pain and quality of life in patients with chronic knee OA and demonstrated an excellent safety profile....
Loading....